QQ客服 官方微博 反馈留言

	Apatinib combined with chemotherapy versus single chemotherapy in HER-2 negative advanced breast cancer: A randomized, controlled, open-label phase II study.
	Chen, Zhanhong; Wang, Xiaojia; Huang, Jian; Zheng, Yabing; Shao, Xiying; Cao, Wenming; Chen, Junqing; Ye, Weiwu; Ping, Huang; Li, Guangliang
刊名	JOURNAL OF CLINICAL ONCOLOGY
	2022-06-01
卷号	40
ISSN号	0732-183X
WOS研究方向	Oncology
语种	英语
出版者	LIPPINCOTT WILLIAMS & WILKINS
WOS记录号	WOS:000863680300244
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/129927]
专题	中国科学院合肥物质科学研究院
作者单位	1.Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Dept Med Oncol Breast, Hangzhou, Peoples R China 2.Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China 3.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Inst Canc & Basic Med ICBM, Chinese Acad Sci,Dept Breast Med Oncol,Canc Hosp, Hangzhou, Peoples R China 4.Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China 5.Zhejiang Canc Hosp, Hangzhou, Peoples R China 6.Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Dept Breast Med Oncol, Hangzhou, Peoples R China 7.Chinese Acad Sci, Inst Canc & Basic Med IBMC, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Chen, Zhanhong,Wang, Xiaojia,Huang, Jian,et al. Apatinib combined with chemotherapy versus single chemotherapy in HER-2 negative advanced breast cancer: A randomized, controlled, open-label phase II study.[J]. JOURNAL OF CLINICAL ONCOLOGY,2022,40.
APA	Chen, Zhanhong.,Wang, Xiaojia.,Huang, Jian.,Zheng, Yabing.,Shao, Xiying.,...&Lou, Caijin.(2022).Apatinib combined with chemotherapy versus single chemotherapy in HER-2 negative advanced breast cancer: A randomized, controlled, open-label phase II study..JOURNAL OF CLINICAL ONCOLOGY,40.
MLA	Chen, Zhanhong,et al."Apatinib combined with chemotherapy versus single chemotherapy in HER-2 negative advanced breast cancer: A randomized, controlled, open-label phase II study.".JOURNAL OF CLINICAL ONCOLOGY 40(2022).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。